Vanda Pharmaceuticals
VNDA
A$7.18
Share price
-0.43%
Change (1 day)
-21.70%
Change (1 year)
Categories
Vanda Pharmaceuticals (VNDA) - Total liabilities
Total liabilities on the balance sheet as of March 2025 : A$0.18 Billion
According to Vanda Pharmaceuticals's latest financial reports the company's total liabilities are A$0.18 Billion. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Vanda Pharmaceuticals - Total liabilities on balance sheet (from 2005 to 2025)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2024-12-31 | A$0.18 B | 24.48% |
| 2023-12-31 | A$0.15 B | -3.4% |
| 2022-12-31 | A$0.15 B | 28.34% |
| 2021-12-31 | A$0.12 B | 17.53% |
| 2020-12-31 | A$0.10 B | 0.29% |
| 2019-12-31 | A$0.10 B | 29.18% |
| 2018-12-31 | A$80.49 M | -15.12% |
| 2017-12-31 | A$94.83 M | -13.52% |
| 2016-12-31 | A$0.10 B | -0.17% |
| 2015-12-31 | A$0.10 B | 725.75% |
| 2014-12-31 | A$13.3 M | -88.04% |
| 2013-12-31 | A$0.11 B | -7.92% |
| 2012-12-31 | A$0.12 B | -16.95% |
| 2011-12-31 | A$0.14 B | -15.75% |
| 2010-12-31 | A$0.17 B | -23.48% |
| 2009-12-31 | A$0.22 B | 3967.48% |
| 2008-12-31 | A$5.54 M | -63.07% |
| 2007-12-31 | A$15.02 M | 24.59% |
| 2006-12-31 | A$12.05 M | 73.37% |
| 2005-12-31 | A$6.95 M | 197.52% |
| 2004-12-31 | A$2.33 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Novartis NVS | A$94.36 B | 50,920.17% | 🇨🇭 Switzerland |
 Eli Lilly LLY | A$112.85 B | 60,921.08% | 🇺🇸 USA |
 Johnson & Johnson JNJ | A$177.34 B | 95,786.96% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | A$115.06 B | 62,113.43% | 🇺🇸 USA |
 Pfizer PFE | A$180.14 B | 97,304.56% | 🇺🇸 USA |
 Titan Pharmaceuticals
TTNP | A$0.42 M | -99.77% | 🇺🇸 USA |
 Merck MRK | A$102.39 B | 55,262.23% | 🇺🇸 USA |